&nbsp;

Jun 2025

Drug

ruxolitinib

Other Name(s): Jakavi®

Quick Link(s):

Mar 2025

Drug

regorafenib

Other Name(s): Stivarga®

Quick Link(s):

Nov 2023

Drug

daBRAFenib

Other Name(s): Tafinlar®

Quick Link(s):

Jun 2025

Drug

romidepsin

Other Name(s): Istodax®

Quick Link(s):

Mar 2023

Drug

ramucirumab

Other Name(s): Cyramza®

Quick Link(s):

Mar 2023

Drug

daratumumab

Other Name(s): Darzalex®

Quick Link(s):

Jan 2023

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

Drugs Used:

daSATinib

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DCRB

Cancer Type:

Sarcoma,

Soft Tissue,

Skin,

Melanoma

Intent: Palliative

Drugs Used:

dacarbazine

Quick Link(s):

Regimen Monograph

Jun 2025

Regimen

DEXA(PO)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

dexamethasone

Quick Link(s):

Regimen Monograph

Sep 2019

Regimen

DOCE(W)PRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

DOCEtaxel,

prednisone

Quick Link(s):

Regimen Monograph

May 2024

Regimen

DOCEPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

prednisone

Drugs Used:

DOCEtaxel,

prednisone